Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Current Deferred Revenue (2016 - 2018)

Heron Therapeutics filings provide 4 years of Current Deferred Revenue readings, the most recent being $14.0 million for Q4 2018.

  • On a quarterly basis, Current Deferred Revenue rose 407.06% to $14.0 million in Q4 2018 year-over-year; TTM through Dec 2018 was $14.0 million, a 407.06% increase, with the full-year FY2018 number at $14.0 million, up 407.06% from a year prior.
  • Current Deferred Revenue hit $14.0 million in Q4 2018 for Heron Therapeutics, up from $10.5 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $14.0 million in Q4 2018 to a low of $1.1 million in Q4 2016.
  • Median Current Deferred Revenue over the past 3 years was $5.2 million (2017), compared with a mean of $6.2 million.
  • The widest YoY moves for Current Deferred Revenue: up 407.06% in 2018, down 55.21% in 2018.
  • Heron Therapeutics' Current Deferred Revenue stood at $1.1 million in 2016, then surged by 151.41% to $2.8 million in 2017, then skyrocketed by 407.06% to $14.0 million in 2018.
  • The last three reported values for Current Deferred Revenue were $14.0 million (Q4 2018), $10.5 million (Q3 2018), and $9.4 million (Q2 2018) per Business Quant data.